PainChek Limited (ASX:PCK), developer of an AI-powered pain assessment and monitoring application, delivered its Chair Address and CEO Presentation at the company's Annual General Meeting on 4 November 2026, disclosing FY2026 financial results, recent commercial wins, and operational metrics as at 30 September 2026.

Key Points

  • Implemented licences increased 27.9% to 90,198 in FY2026, with implemented annual recurring revenue increasing 24.6% to $4.46 million
  • The Group recorded a loss after tax of $8.9 million for FY2026, with cash receipts from customers increasing 13.6% to $4 million
  • Sabra Health Care's contracted sites expanded from two to 23 across five operators, covering 808 licences, with activation targeted for completion by 31 December 2026
  • UK contract secured with Hallmark Luxury Care Homes covering 23 homes and approximately 1,800 licences, with rollout scheduled to start in late January 2027
  • September quarter unaudited customer revenue increased 12.9% compared with the June quarter to $1.210 million, with customer retention improving from 85% to 90%

FY2026 Financial and Operational Results

For the financial year ended 2026, PainChek reported recognised customer revenue of $3.74 million and cash receipts from customers of $4 million, representing a 13.6% increase. Implemented licences grew 27.9% to 90,198, while implemented annual recurring revenue rose 24.6% to $4.46 million. The Group recorded a loss after tax of $8.9 million. As at 30 September 2026, the company reported 24.49 million assessments completed, 2,076 activated customer sites, and a 90% customer retention rate across more than 30 care management integrations.

US Market Entry and FDA De Novo Clearance

The company disclosed that US FDA De Novo clearance was received in October 2025, establishing PainChek Adult as the first regulated medical device available in the United States for assessing pain in individuals unable to reliably verbalise their pain, and creating a new FDA classification for this category of technology. PainChek commenced commercial deployment in the US during FY2026. In April 2026, the company signed a Master Services Agreement with Sabra Health Care, providing a framework to pursue deployment across facilities representing up to 20,000 beds. A paid pilot with Silverado covers 203 licences across two memory care sites, with broader rollout subject to evaluation and further agreements.

Board and Executive Changes and Commercial Priorities

Lil Bianchi was appointed Non-Executive Chair on 25 May 2026, with a remit to appoint a CEO and strengthen the team. Karen Holzberger commenced as CEO on 17 August 2026. The company disclosed that resources are now concentrated on residential aged care, with the priority segment estimated at 2.19 million potential licences within a total addressable market of approximately 9.27 million potential licences across the US, UK, ANZ and Canada. The US residential aged care opportunity is estimated at A$100 million across 1.2 million potential licences. These estimates were described as not contracted nor revenue guidance. A two-site paid pilot has been agreed with AgeCare in Canada.